Authors: Archana Karadkhele, Gaurav Puppalwar, Manish R Pandya, Rishi Jain
Background: Vulvo-vaginal infection (VVI) often results in abnormal vaginal discharge, soreness, redness and pain during urination. As per CDC 2017, vulvovaginitis is a second common infection. For management of VVI, both oral and topical preparations are available. But, there is scarcity of data on prevalent clinical practices in the management of VVI in India. Materials and Methods: This cross-sectional, non-interventional, observational, multicentric, questionnaire based survey was conducted with 992 gynaecologists across India. A series of 10 multiple choice questions were prepared. The questionnaire was targeted on prevalent practices in topical management of patients with VVI. All the parameters were summarized using descriptive statistics. Results: Majority of the gynaecologists (N=772/992, 78%) in the survey responded that they treat approximately 10 patients with VVI per week. About 54% of gynaecologists (N=532/992) consider pH of the topical preparation as an important parameter. Nearly, 82% of gynaecologists (N=818/992) prefer using a lower potency steroid like mometasone for application on genital areas instead of higher potency steroid like clobetasol. About 98% of gynaecologists were satisfied (67%; N=664/992) to very satisfied (31%; N=312/992) with the use of triple drug topical combination of nadifloxacin, terbinafine and mometasone in the management of VVI. Conclusion: This survey concluded that VVI is commonly seen in gynaecological practice in India. Further more, triple drug topical combination of antibiotic, antifungal and steroid is generally preferred by gynaecologists in the management of VVI with satisfactory results. Keywords: Vulvo-vaginal infection, Nadifloxacin, Terbinafine, Mometasone.
Open full article page